Table 2.

Summary of Treatment-Emergent AEs by Class

	Dose of Efatutazone (bid)			Overall (n = 15)
	0.15 mg (n = 7)	0.30 mg (n = 6)	0.50 mg (n = 2)
Any AEa	6	6	2	14
Any AE of grade 3 or greater	3	5	2	10
Any AE attributed to efatutazone	4	4	2	10
AE of grade 3 or greater attributed to efatutazone	0	2	0	2
SAE leading to treatment discontinuationb	1	0	1	2
Patient deathsc	2	0	0	2
DLTs	0	0	0	0

^aAEs that began or worsened after dispensation of study drug.

^bNo patients discontinued therapy due to events attributed to efatutazone.

^cTwo subjects died because of disease progression; there were no therapy-related deaths.